Methoden vergleichen
Prüfen Sie die ausgewählten Methoden nebeneinander; abweichende Zeilen sind hervorgehoben.
| Emax-Modell: Pharmakodynamische Dosis-Wirkungs-Analyse× | Pharmakokinetisches Kompartimentmodell× | |
|---|---|---|
| Fachgebiet | Pharmakometrie | Pharmakometrie |
| Familie | Regression model | Regression model |
| Entstehungsjahr≠ | 1981 | 1982 |
| Urheber≠ | Holford & Sheiner | Gibaldi & Perrier |
| Typ≠ | Nonlinear dose-response regression model | Deterministic ODE-based pharmacokinetic model |
| Wegweisende Quelle≠ | Holford, N. H. G., & Sheiner, L. B. (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6(6), 429–453. DOI ↗ | Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker. ISBN: 978-0-8247-1042-2 |
| Aliasnamen | Maximum Effect Model, Hyperbolic Emax Model, Sigmoidal Emax Model, Emax Farmakodynamik Modeli | Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli |
| Verwandt≠ | 2 | 3 |
| Zusammenfassung≠ | The Emax model is a nonlinear pharmacodynamic model that describes the relationship between drug concentration and biological effect. Introduced by Holford and Sheiner in 1981, it characterizes dose-response curves using three fundamental parameters: the maximum achievable effect (Emax), the concentration producing half-maximal effect (EC50), and an optional baseline effect (E0). It remains the standard framework in clinical pharmacology and drug development for quantifying pharmacodynamic dose-response relationships. | The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses. |
| ScholarGateDatensatz ↗ |
|
|